BioHarvest Sciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BHST research report →
Range $5 – $5
Price Chart
About the company
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients.
- CEO
- Zaki Rakib
- IPO
- 2021
- Employees
- 89
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on BHST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.53M
- P/E
- -2.24
- Fwd P/E
- 390.04
- PEG
- -0.11
- P/S
- 0.62
- P/B
- 1.66
- EV/EBITDA
- -2.62
- Div Yield
- 0.00%
- Gross Margin
- 57.12%
- Op Margin
- -24.81%
- Net Margin
- -34.67%
- ROE
- -55.88%
- ROIC
- -24.48%
Latest fiscal year · YoY change
- Revenue
- $34.51M+37.0%
- Gross Profit
- $20.48M+46.9%
- Op Income
- $-5,575,000
- Net Income
- $-11,135,000+13.8%
- EPS
- $-0.60+25.0%
- OCF Growth
- -8.1%
- FCF Growth
- -0.7%
- 52W High
- $7.20
- 52W Low
- $0.91
- 50D MA
- $1.59
- 200D MA
- $3.00
- Beta
- 1.31
- RSI (14)
- 40
- Avg Volume
- 29.59K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BioHarvest posted lower Q3 revenue and margins as it intentionally slowed VINIA customer acquisition and refocused CDMO spending, while guiding to cash preservation and a 2027 growth reset.· November 12, 2026
- Q3 revenue fell to $7.9 million from $9.1 million a year ago, with gross profit of $4.2 million and gross margin of 54% versus 61%.
- Net loss widened to $3.3 million, or $0.15 per share, and adjusted EBITDA loss was $2.0 million.
- Management said it deliberately reduced lower-return VINIA marketing and concentrated CDMO work on a smaller set of higher-potential programs.
- Full-year 2026 guidance was cut to $32.0 million-$33.5 million of revenue and an adjusted EBITDA loss of $5.5 million-$7.5 million.
- The company expects VINIA DTC to re-accelerate in Q1 2027 and sees first manufacturing revenue from the fragrance program in the second half of 2027.
Third-quarter 2026 revenue was $7.9 million, down from $9.1 million in the same quarter last year. Gross profit was $4.2 million, or 54% of revenue, versus $5.6 million, or 61%, a year ago. Net loss was $3.3 million, or $0.15 per basic and diluted share, compared with a net loss of $2.5 million, or $0.14 per share, last year. Adjusted EBITDA loss was $2.0 million versus $400,000 in the prior-year quarter. Cash and cash equivalents plus bank deposits were $12.5 million at September 30, 2026. For full-year 2026, management now expects consolidated revenue of $32.0 million to $33.5 million and an adjusted EBITDA loss of $5.5 million to $7.5 million. VINIA direct-to-consumer revenue guidance was revised to $31.0 million to $32.0 million; external CDMO revenue is expected to be $1.0 million to $1.5 million with an adjusted EBITDA loss of $4.0 million to $5.0 million.
Zaki Rakib framed the quarter as a deliberate transition rather than a broad operational miss, saying the company is shifting to higher-quality VINIA growth and concentrating CDMO resources on programs that can reach manufacturing sooner. He emphasized cash preservation, phased manufacturing capacity additions, and reducing fixed costs, including consolidating development sites in 2027. His tone was defensive but optimistic, especially around the fragrance program, which he described as a high-margin opportunity and a key focus for 2027.
Bar Dichter detailed the year-over-year declines in revenue and margin and tied them to the planned shift in the product business and the timing of CDMO development revenue. He said cost of revenue was $3.6 million versus $3.5 million last year, R&D was $1.8 million versus $1.4 million, sales and marketing was $4.0 million versus $4.1 million, and G&A was $1.5 million versus $900,000. He also noted cash and bank deposits of $12.5 million and said management is aligning spending with cash preservation, with 2027 CapEx targeted below $5 million.
Analysts focused on why the company bought back shares while emphasizing cash preservation, and management said the buyback was modest and would not cause accelerated cash depletion. Questions also centered on when CDMO cash flow would arrive; Zaki said revenue could come from development work, molecule licensing, and fragrance manufacturing, with manufacturing revenue expected in the second half of next year. On VINIA, management said Q3 and Q4 are expected to be lower as the marketing reset takes hold, with growth expected to resume in Q1 2027.
Management sees a clearer path to higher-value CDMO revenue, including a signed manufacturing and supply agreement for the rare fragrance program and an estimate of $20 million to $30 million of revenue over 2027-2028. VINIA is being reset toward better economics rather than abandoned, and the company expects the changes to begin showing benefits in Q1 2027. Cash discipline appears real, with CapEx targeted below $5 million in 2027 and capacity additions to be phased with demand.
The near-term picture is weaker: revenue, gross margin, net loss and adjusted EBITDA all deteriorated versus last year, and full-year guidance was lowered. Management acknowledged that the VINIA transition will keep Q3 and Q4 moderately lower and that CDMO revenue is being delayed by resource concentration on one priority program. Execution risk remains high because future revenue depends on successful development, partner timing, manufacturing readiness and the ability to monetize the fragrance program and other molecules as planned.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.9%
- Shares Outstanding
- 17.33M
- Float Shares
- 14.53M
of shares held by institutions
18 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Alyeska Investment Group, L.P. | 581.44K | ▼ 175.62K |
| Thompson Siegel & Walmsley LLC | 364.01K | 0 |
| Evercore Wealth Management, LLC | 216.34K | ▲ 76.87K |
| Susquehanna International Group, Llp | 63.66K | ▲ 47.26K |
| Hrt Financial LP | 52.65K | ▲ 52.65K |
| King Luther Capital Management Corp | 40.00K | 0 |
| Citadel Advisors LLC | 20.65K | ▲ 5.90K |
| Jane Street Group, LLC | 13.50K | ▲ 13.50K |
| Xtx Topco Ltd | 13.23K | ▼ 16.42K |
| K.J. Harrison & Partners Inc | 10.00K | 0 |
| Morgan Stanley | 6.47K | ▲ 3.23K |
| Ubs Group AG | 5.04K | ▲ 4.87K |
Our BHST coverage
Recent articles, reports, and earnings notes.
No research on BHST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BHST report →BioHarvest Sciences Inc. (BHST) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 12
BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update
newsfilecorp.com · Nov 12
BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) Head to Head Contrast
defenseworld.net · Nov 6
Solesence (NASDAQ:SLSN) versus BioHarvest Sciences (NASDAQ:BHST) Financial Review
defenseworld.net · Nov 6
BioHarvest Sciences (NASDAQ:BHST) & Interparfums (NASDAQ:IPAR) Head to Head Analysis
defenseworld.net · Nov 5
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
newsfilecorp.com · Oct 29
BioHarvest takes second plant-cell asset to commercial readiness
proactiveinvestors.com · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.